Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders

MC Michel, L Cardozo, CJ Chermansky, F Cruz… - Pharmacological …, 2023 - ASPET
Overactive bladder syndrome with and without urinary incontinence and related conditions,
signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract …

[HTML][HTML] Emerging drugs for the treatment of bladder storage dysfunction

KE Andersson - Expert Opinion on Emerging Drugs, 2022 - Taylor & Francis
Introduction Current drug treatment of lower urinary tract disorders, for example, overactive
bladder syndrome and lower urinary tract symptoms associated with benign prostatic …

Flexible‐dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double‐blind, placebo‐controlled study of fesoterodine in an aging …

A Wagg, V Khullar, D Marschall‐Kehrel… - Journal of the …, 2013 - Wiley Online Library
Objectives To assess the efficacy and safety of flexible‐dose fesoterodine in elderly adults
with overactive bladder (OAB). Design Twelve‐week, randomized, double‐blind, placebo …

Management strategies for neurogenic lower urinary tract dysfunction: a qualitative study of the experiences of people with multiple sclerosis and healthcare …

HB Al Dandan, R Galvin, D McClurg… - Disability and …, 2022 - Taylor & Francis
Purpose Urinary symptoms are highly prevalent among people with MS. This study aimed to
explore the experiences of people with MS and HCPs in managing urinary symptoms and …

Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the …

D Staskin, J Owens-Grillo, E Thomas, E Rovner… - Journal of …, 2024 - journals.lww.com
Purpose: Efficacy and safety of vibegron, a β 3-adrenergic receptor agonist, was assessed
among men with symptoms of overactive bladder (OAB) receiving pharmacologic treatment …

[HTML][HTML] Патогенетическое обоснование использования ингибиторов 5-альфа редуктазы в лечении доброкачественной гиперплазии предстательной железы

ОВ Золотухин, АВ Есин… - … и клиническая урология, 2022 - cyberleninka.ru
Введение. Доброкачественная гиперплазия предстательной железы (ДГПЖ) является
одним из наиболее распространенных урологических заболеваний. На сегодняшний …

[HTML][HTML] Prostatic Therapeutic Efficacy of LENILUTS®, a Novel Formulation with Multi-Active Principles

E Tedesco, F Benetti, S Castelli, A Fratter - Pharmaceutics, 2022 - mdpi.com
Lower Urinary Tract Symptoms (LUTs) in men are usually associated to benign prostatic
hyperplasia (BPH), a non-malignant prostate enlargement. Unfortunately, BPH etiology is …

[PDF][PDF] The effects of silodosin therapy on the parameters and patterns of ureteric jets in patients with lower urinary tract symptoms.

MY Salman, KM Altintoprak, TY Kuzan… - European Review for …, 2023 - europeanreview.org
OBJECTIVE: To our knowledge, there is no study in the literature so far to investigate the
effect of silodosin therapy on the ureteric jet parameters. Therefore, the objective of this …

[HTML][HTML] Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study

G Theil, M Richter, M Schulze, T Köttig, B Patz… - World Journal of …, 2022 - Springer
Purpose To assess the symptoms, quality of life and sexual well-being in patients with lower
urinary tract symptoms due to benign prostatic hyperplasia LUTS/BPH treated with pumpkin …

An in Vitro Investigation of Urothelial Cell Function in Response to Hypoxia and Pressure in Relation to Bladder Outlet Obstruction

B Hudson - 2024 - tigerprints.clemson.edu
Bladder outlet obstruction (BOO) is a prevalent urological condition and can be
characterized by the presence of lower urinary tract symptoms (LUTS), such as hesitancy …